Log in

AnaptysBio Stock Forecast, Price & News

+0.30 (+2.10 %)
(As of 09/28/2020 05:31 AM ET)
Today's Range
Now: $14.60
50-Day Range
MA: $16.58
52-Week Range
Now: $14.60
Volume224,900 shs
Average Volume419,874 shs
Market Capitalization$398.64 million
P/E RatioN/A
Dividend YieldN/A
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation. AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd., including an anti-PD-1 antagonist antibody (TSR-042), an anti-TIM-3 antagonist antibody (TSR-022), and an anti-LAG-3 antagonist antibody (TSR-033); and an inflammation partnership with Celgene Corporation, including an anti-PD-1 checkpoint agonist antibody (CC-90006) in clinical development. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California.
Read More
AnaptysBio logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.9Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.87 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ANAB



Sales & Book Value

Annual Sales$8 million
Book Value$14.93 per share


Net Income$-97,340,000.00


Market Cap$398.64 million
Next Earnings Date11/13/2020 (Estimated)
+0.30 (+2.10 %)
(As of 09/28/2020 05:31 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ANAB News and Ratings via Email

Sign-up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

AnaptysBio (NASDAQ:ANAB) Frequently Asked Questions

How has AnaptysBio's stock price been impacted by Coronavirus (COVID-19)?

AnaptysBio's stock was trading at $15.23 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ANAB shares have decreased by 4.1% and is now trading at $14.60.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of AnaptysBio?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last year. There are currently 1 sell rating and 6 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for AnaptysBio

When is AnaptysBio's next earnings date?

AnaptysBio is scheduled to release its next quarterly earnings announcement on Friday, November 13th 2020.
View our earnings forecast for AnaptysBio

How were AnaptysBio's earnings last quarter?

AnaptysBio Inc (NASDAQ:ANAB) announced its quarterly earnings data on Monday, August, 10th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.75) by $0.04.
View AnaptysBio's earnings history

What price target have analysts set for ANAB?

7 equities research analysts have issued 1-year price objectives for AnaptysBio's stock. Their forecasts range from $12.00 to $17.00. On average, they expect AnaptysBio's share price to reach $15.20 in the next year. This suggests a possible upside of 4.1% from the stock's current price.
View analysts' price targets for AnaptysBio

Who are some of AnaptysBio's key competitors?

What other stocks do shareholders of AnaptysBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include bluebird bio (BLUE), ImmunoGen (IMGN), NVIDIA (NVDA), Amarin (AMRN), Crispr Therapeutics (CRSP), Editas Medicine (EDIT), Illumina (ILMN), Clovis Oncology (CLVS), Twilio (TWLO) and AbbVie (ABBV).

Who are AnaptysBio's key executives?

AnaptysBio's management team includes the following people:
  • Mr. Hamza Suria, Pres, CEO & Director (Age 43)
  • Mr. Dominic G. Piscitelli M.B.A., CPA, Chief Financial Officer (Age 44)
  • Prof. Marco Londei, Chief Medical Officer (Age 62)
  • Mr. Eric J. Loumeau, Gen. Counsel (Age 56)
  • Dr. Hemant Kumar, Sr. VP of Manufacturing

When did AnaptysBio IPO?

(ANAB) raised $60 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is AnaptysBio's stock symbol?

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

Who are AnaptysBio's major shareholders?

AnaptysBio's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.26%), Federated Hermes Inc. (5.19%), BVF Inc. IL (4.74%), Cormorant Asset Management LP (3.24%), Two Sigma Advisers LP (1.50%) and Goldman Sachs Group Inc. (1.26%). Company insiders that own AnaptysBio stock include Dominic Piscitelli, Hamza Suria and Marco Londei.
View institutional ownership trends for AnaptysBio

Which institutional investors are selling AnaptysBio stock?

ANAB stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Krensavage Asset Management LLC, Cormorant Asset Management LP, Bank of America Corp DE, Vanguard Group Inc., State Board of Administration of Florida Retirement System, PDT Partners LLC, and Engineers Gate Manager LP.
View insider buying and selling activity for AnaptysBio

Which institutional investors are buying AnaptysBio stock?

ANAB stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Point72 Asset Management L.P., Federated Hermes Inc., FMR LLC, FMR LLC, Globeflex Capital L P, Alps Advisors Inc., and Jacobs Levy Equity Management Inc..
View insider buying and selling activity for AnaptysBio

How do I buy shares of AnaptysBio?

Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AnaptysBio's stock price today?

One share of ANAB stock can currently be purchased for approximately $14.60.

How big of a company is AnaptysBio?

AnaptysBio has a market capitalization of $398.64 million and generates $8 million in revenue each year. The biotechnology company earns $-97,340,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis. AnaptysBio employs 78 workers across the globe.

What is AnaptysBio's official website?

The official website for AnaptysBio is www.anaptysbio.com.

How can I contact AnaptysBio?

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-362-6295 or via email at [email protected]

This page was last updated on 9/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.